Market news

Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.

The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.

Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix (NASDAQ:ONCO) stock rose

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable arbitration resolution with Beam Therapeutics affirms Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency; IND and/or CTA submission expected in 3Q 2026, with initial clinical data in 2027 -- -- FDA grants Regenerative Medicine Advanced Therapy designation to PM359; co

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ther

Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, […]

Detailed price information for Resmed Inc (RMD-N) from The Globe and Mail including charting and trades.

In late June 2026, an arbitration tribunal ruled that Prime Medicine did not breach its 2019 collaboration agreement with Beam Therapeutics and can continue developing PM647, an investigational gene-editing therapy for Alpha-1 Antitrypsin Deficiency, without paying damages to Beam. This outcome narrows Beam’s control over the AATD opportunity and adds a new competitor in a disease area central to its liver portfolio. Next, we’ll examine how losing exclusive rights around AATD to Prime...

Prime Medicine won a legal battle with Beam Therapeutics on Wednesday. Prime shares jumped while Beam stock skidded.

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class o

An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency falls within its rights under a 2019 collaboration agreement with Beam Therapeutics.

An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.

Prime Medicine, Inc. (NASDAQ:PRME) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Multiple regulatory clearances across its gene-editing pipeline are prompting analysts to turn more constructive on the stock. On June 29, 2026, H.C. Wainwright upgraded Prime Medicine, Inc. (NASDAQ:PRME) to “Buy” from “Neutral” with a price target […]